GO
Loading...

Express Scripts Holding Co

More

  • Cramer's game plan: Expect major news on this Friday, 20 Feb 2015 | 6:15 PM ET
    Spanish Finance Minister Luis de Guindos, left, talks with Greek Finance Minister Yanis Varoufakis at a euro zone finance ministers meeting to discuss Athens' plans to reverse austerity measures, in Brussels, Feb. 20, 2015.

    With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.

  • US still the place to be: Delphi's Scott Black Friday, 20 Feb 2015 | 3:47 PM ET
    Traders work on the floor of the New York Stock Exchange Feb. 20, 2015.

    U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.

  • Buffett's Berkshire builds Deere stake, dumps Exxon Wednesday, 18 Feb 2015 | 7:19 AM ET
    A John Deere 8600 tractor is displayed on opening day of the World Ag Expo on February 10, 2015 in Tulare, Calif.

    Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.

  • NEW YORK, Feb 17- Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a 5 percent stake in agricultural equipment maker Deere& Co and said it shed a $3.74 billion investment in oil company Exxon Mobil Corp as oil prices plunged. The changes were among several that Berkshire made in its common stock investments in the fourth quarter, according to a U.S....

  • Drug price wars 'drive value': Medical exec Friday, 6 Feb 2015 | 5:21 PM ET
    Hepatitis C sufferers and supporters hold placards during a demonstration outside of US laboratory Gilead Sciences office in Madrid on February 5, 2015.

    Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...

  • Drugmaker AbbVie beats as Humira sales rise Friday, 30 Jan 2015 | 11:34 AM ET
    AbbVie facility in Ireland

    U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.

  • Jan 30- U.S. drugmaker AbbVie Inc's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent. Excluding the charge and other special items, AbbVie earned 89 cents per share. Sales of Humira, which AbbVie inherited from Abbott Laboratories in 2013, rose to $3.36 billion in the fourth quarter ended...

  • Trend trader: Playing a euro fall to parity Friday, 30 Jan 2015 | 7:00 AM ET

    From a U.S. trading perspective, here are the ways to play the strengthening dollar of 2015.

  • Jan 26- Pharmacy benefits manager EnvisionRx said on Monday it reached an agreement to provide its customers with Gilead Sciences Inc's hepatitis C drugs on an exclusive basis, the latest Gilead victory in a market share battle with AbbVie over their new treatments for the liver destroying virus. EnvisionRx said Gilead's Sovaldi and its newer two-drug...

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...

  • Cramer's guide to a treacherous trader's market Tuesday, 13 Jan 2015 | 6:14 PM ET
    Sailboat in rough seas

    One minute it's up, the next minute it's down. Jim Cramer gives two important tips for navigating the rough seas of a volatile market.

  • Jan 8- Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus. Last month, AbbVie Inc began sales of a competing drug, Viekira Pak, at a similar list price. Express Scripts Holding Co, the...

  • Jan 8- AbbVie Inc forecast 2015 earnings largely above analysts' average estimate, betting on its recently approved hepatitis C drug and growth in its auto-immune disease treatment, Humira. U.S. health regulators approved Viekira Pak, AbbVie's all-oral treatment for hepatitis C in December. AbbVie's newly approved regimen is also cheaper than Gilead's...

  • Jan 5- CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from AbbVie Inc only as an exception. The latest salvo in the battle to grab market share for new all-oral treatments for the liver-destroying hepatitis C virus follows...

  • Gilead fights back: CVS deal sends shares soaring Monday, 5 Jan 2015 | 1:05 PM ET
    Pedestrians walk by a CVS store in San Francisco.

    Gilead Sciences' hepatitis C drugs, Sovaldi and Harvoni, will get exclusive coverage on several plans from CVS/Caremark.

  • Drug pricing concerns? Not at Gilead Monday, 5 Jan 2015 | 10:41 AM ET
    A scientist at Gilead Sciences' laboratory in Foster City, Calif.

    Despite drug pricing concerns that weighed on Gilead Sciences' stock toward the end of December, the drugmaker started the year by raising prices.